u-s-allows-emergency-use-of-eli-lillys-covid-19-antibody-therapy-idUSKBN27P35L

Whoao Black Betty bamlanivimab

The Food and Drug Administration (FDA) granted emergency use authorization (EUA) to Eli Lilly & Co’s bamlanivimab based on trial data showing that a one-time infusion of the treatment reduced the need for hospitalization or emergency room visits in high-risk COVID-19 patients.